NASDAQ:ENOB Enochian Biosciences (ENOB) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ENOB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.40▼$0.7952-Week Range N/AVolume88,300 shsAverage Volume137,347 shsMarket Capitalization$40.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Enochian Biosciences alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Enochian Biosciences Stock (NASDAQ:ENOB)Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! ENOB Stock News HeadlinesMarch 2, 2024 | msn.comCITY WHISPERS: Dr No's firm in rebrand after Hindenburg disasterFebruary 13, 2024 | msn.comRenovaro Biosciences Faces Turmoil After Hindenburg Report Accusing Questionable Merger And Governance, Stock CrashesApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.November 23, 2023 | investing.comEastern & Oriental Bhd (ENOB)October 24, 2023 | benzinga.comAkoya Biosciences Stock (NASDAQ:AKYA), Analyst Ratings, Price Targets, PredictionsOctober 3, 2023 | theglobeandmail.comRenovaro BioSciences (NASDAQ: RENB) CEO Releases Shareholder LetterSeptember 30, 2023 | theglobeandmail.comRenovaro BioSciences (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi CubeSeptember 11, 2023 | barrons.comRenovaro Biosciences Inc.April 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.September 3, 2023 | investing.comRenovaro Biosciences Inc (RENB)August 21, 2023 | finance.yahoo.comRenovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical OfficerAugust 10, 2023 | finance.yahoo.comRenovaro BioSciences, GEDi Cube Announce LOI to Merge, Focus on Fight Against CancerAugust 9, 2023 | finance.yahoo.comAI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against CancerJuly 25, 2023 | finance.yahoo.com3 Doomed Biotech Stocks Destined for DisasterJune 23, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder MeetingJune 23, 2023 | finance.yahoo.comEnochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder MeetingJune 8, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewJune 8, 2023 | finance.yahoo.comEnochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewApril 15, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)April 3, 2023 | finance.yahoo.comEnochian BioSciences’ CEO Letter to ShareholdersMarch 29, 2023 | finance.yahoo.comEnochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading ResearcherMarch 13, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsMarch 13, 2023 | msn.comEnochian BioSciences regains Nasdaq compliance by filing pending reportsMarch 13, 2023 | finance.yahoo.comEnochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsFebruary 23, 2023 | msn.comEnochian gets Nasdaq listing deficiency notice for not filing 10-QFebruary 23, 2023 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022January 19, 2023 | reuters.comENOB.O - | Stock Price & Latest News | ReutersSee More Headlines Receive ENOB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENOB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone(305) 918-1980FaxN/AEmployees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-154.69% Return on Assets-130.66% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / BookN/AMiscellaneous Outstanding Shares58,280,000Free Float45,625,000Market Cap$40.80 million OptionableNot Optionable Beta1.09 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Mark R. Dybul M.D. (Age 60)CEO, Director & Member of HBV Scientific Advisory Board Comp: $950kMs. Luisa Puche (Age 59)CFO & Corp. Sec. Comp: $403.75kDr. Serhat GümrükcüCo-Founder & InventorDr. Francois Binette M.Sc. (Age 59)Ph.D., Chief Operating Officer Mr. Greg Duczynski Ph.D.Sr. VP for Clinical OperationsKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPCleneNASDAQ:CLNNEledon PharmaceuticalsNASDAQ:ELDNMarker TherapeuticsNASDAQ:MRKRUnicycive TherapeuticsNASDAQ:UNCYView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 300 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCBought 400 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions ENOB Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Enochian Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and This page (NASDAQ:ENOB) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enochian Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.